Overview
Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026
Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38
Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025
Outlook
Citius anticipates growth from international market expansion and oncology franchise development
Company plans to expand LYMPHIR access in Europe and the Middle East
Citius focuses on technology-driven platform to enhance market penetration
Result Drivers
LYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025
AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetration
INTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient Programs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Net Income | -$8.20 mln | ||
Q1 Basic EPS | -$0.38 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79
The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months ago
Press Release: ID:nPn7wjdcta
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)